1. Search Result
Search Result
Results for "

cholesterol biosynthesis

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

3

Biochemical Assay Reagents

17

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113342

    Endogenous Metabolite Metabolic Disease
    7-Ketocholesterol, toxic oxysterol, inhibits the rate-limiting step in bile acid biosynthesis cholesterol 7 alpha-hydroxylase, as well as strongly inhibiting HMG-CoA reductase (the rate-limiting enzyme in cholesterol biosynthesis). 7-Ketocholesterol induces cell apoptosis .
    7-Ketocholesterol
  • HY-N10232

    Others Infection
    Agistatin E is a pyranacetal originally isolated from a Fusarium sp. that inhibits the cholesterol biosynthesis .
    Agistatin E
  • HY-N10231

    Others Infection Inflammation/Immunology
    Agistatin D is a pyranacetal originally isolated from a Fusarium sp. that inhibits the cholesterol biosynthesis .
    Agistatin D
  • HY-139576

    DUR-928

    Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol
  • HY-139576A

    DUR-928 sodium

    Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol sodium
  • HY-139576B

    DUR-928 (trimethylamine)

    LXR Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol (trimethylamine)
  • HY-14925
    Lapaquistat
    1 Publications Verification

    T-91485

    Endogenous Metabolite Drug Metabolite Metabolic Disease
    Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .
    Lapaquistat
  • HY-107420
    AY 9944
    2 Publications Verification

    Others Metabolic Disease
    AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC50 of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol .
    AY 9944
  • HY-125666

    Others Infection
    Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits cholesterol synthesis .
    Agistatin B
  • HY-122410

    Cytochrome P450 Others
    Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor. .
    Dihydrolanosterol
  • HY-104051

    Antibiotic MB 530A; Lovastatin diol lactone

    HMG-CoA Reductase (HMGCR) Autophagy Metabolic Disease
    Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase.
    Monacolin J
  • HY-113224
    Desmosterol
    4 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Desmosterol is a molecule similar to cholesterol. Desmosterol is the immediate precursor of cholesterol in the Bloch pathway of cholesterol biosynthesis. Desmosterol, as an endogenous metabolite, used to study cholesterol metabolism .
    Desmosterol
  • HY-157528

    Endogenous Metabolite Cancer
    CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .
    CJ28
  • HY-B1189

    Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid

    HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Cardiovascular Disease
    Meglutol is an antilipidemic agent that lowers cholesterol, triglycerides, and serum beta-lipoproteins and phospholipids, and inhibits hydroxymethylglutaryl-CoA reductase activity, which is the rate-limiting enzyme in cholesterol biosynthesis.
    Meglutol
  • HY-114297

    Endogenous Metabolite Others
    Zymosterol is a Cholesterol (HY-N0322) biosynthesis metabolite. Zymosterol, a precursor of Cholesterol, is found mostly in the plasma membrane. Zymosterol circulates within the cell .
    Zymosterol
  • HY-113224S

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Desmosterol-d6 is the deuterium labeled Desmosterol. Desmosterol is a molecule similar to cholesterol. Desmosterol is the immediate precursor of cholesterol in the Bloch pathway of cholesterol biosynthesis. Desmosterol, as an endogenous metabolite, used to study cholesterol metabolism[1].
    Desmosterol-d6
  • HY-122410S

    Isotope-Labeled Compounds Cytochrome P450 Others
    Dihydrolanosterol-d7 is deuterium labeled Dihydrolanosterol. Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor[1].
    Dihydrolanosterol-d7
  • HY-B1189S

    Dicrotalic acid-d3; 3-Hydroxy-3-methylglutaric acid-d3

    Autophagy HMG-CoA Reductase (HMGCR) Endogenous Metabolite Cardiovascular Disease
    Meglutol-d3 is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
    Meglutol-d3
  • HY-137178

    Endogenous Metabolite Metabolic Disease
    20α,22R-Dihydroxycholesterol is an endogenous metabolic intermediate. 20α,22R-Dihydroxycholesterol involved in the biosynthesis of cholesterol to steroid hormones .
    20α,22R-Dihydroxycholesterol
  • HY-16274

    TAK-475

    Others Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-113345

    5a-Cholest-8-en-3b-ol

    Endogenous Metabolite ROR Cancer
    Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a RORγ agonist (EC50: 1 μM) .
    Zymostenol
  • HY-133971

    5α,6α-Epoxycholesterol

    Biochemical Assay Reagents Others
    Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.
    Cholesterol 5α,6α-epoxide
  • HY-116572A

    Others Cancer
    TASIN-1 is a selective inhibitor of truncated APC gene (adenomatous polyposis coli gene) and exerts cytotoxic effects through inhibition of cholesterol biosynthesis. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC .
    TASIN-1
  • HY-N7392

    Biochemical Assay Reagents Metabolic Disease
    Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
    Acetoacetyl-CoA
  • HY-114294A

    Biochemical Assay Reagents Metabolic Disease
    DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
    DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium
  • HY-B0444A

    Autophagy Neurological Disease Cancer
    Maprotiline is a highly selective noradrenergic reuptake blocker, has strong antidepressant efficacy. Maprotiline induces cancer cells apoptosis by targeting ERK signaling pathway and CRABP1. Maprotiline restrains cell proliferation and metastasis, exhibits anticancer effect .
    Maprotiline
  • HY-158050

    c-Fms
    PXB17 can inhibit CSF1R (IC50 = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .
    PXB17
  • HY-10016
    E 2012
    Maximum Cited Publications
    6 Publications Verification

    γ-secretase Neurological Disease
    E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .
    E 2012
  • HY-113259

    Endogenous Metabolite Metabolic Disease
    7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
    7α-Hydroxy-4-cholesten-3-one
  • HY-113259S

    Endogenous Metabolite Metabolic Disease
    7α-Hydroxy-4-cholesten-3-one-d7 is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1[1][2].
    7α-Hydroxy-4-cholesten-3-one-d7
  • HY-113259R

    Endogenous Metabolite Metabolic Disease
    7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
    7α-Hydroxy-4-cholesten-3-one (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: